title: Trazodone in major affective disorders.
abstract: In summary, on the basis of our inpatient and outpatient double-blind control trials and open-label experience with trazodone, we find it to be an effective broad-spectrum antidepressant generally well tolerated by most patients. When atropine side effects of the standard tricyclic antidepressants and bridged tricyclic antidepressants are undesirable and medically contraindicated, trazodone should be one of the drugs of choice in major depressive disorders.
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007099:Imipramine / Q000009:adverse effects / Q000627:therapeutic use; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D011569:Psychiatric Status Rating Scales; D014196:Trazodone / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D010879:Piperazines; D007099:Imipramine; D014196:Trazodone